This series on “Current Issues on GEJ Adenocarcinoma” is edited by Prof. Riccardo Rosati, from Gastrointestinal Surgery Division, Vita-Salute University - San Raffaele Hospital, Milan, Italy.
Surgery is no longer the only way to treat this aggressive disease. A multimodal approach with preoperative chemo and chemo-radiotherapy is the standard care in most cases and the evaluation of the response to these treatments with new techniques such as MRI, represent a new field of investigation and development. Identification and prediction of response to various treatment modalities is a very promising field of research for proper patient selection. An important step forward has also been made with the development of endoscopic resection for early stage disease, avoiding “overtreatment”, leaving intact the esophageal function with a better long term quality of life.
Total gastrectomy versus upper pole gastrectomy for the surgical therapy of Siewert type II adenocarcinoma of the esophagus: pathology may drive the choice
Surgical treatment of Siewert type II gastroesophageal junction cancer: esophagectomy, total gastrectomy or other options?
Current approaches to clinical research with respect to esophageal resection: are online clinical datasets the future?
The series “Current issues on GEJ Adenocarcinoma” was commissioned by the editorial office, Annals of Esophagus without any sponsorship or funding. Riccardo Rosati is serving as the unpaid Guest Editor for the series.